All 4 of these stocks are trading at a discount to their historical average. These companies have the ability to outperform regardless of the economic backdrop.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Bristol Myers' (BMY) Sotyktu gets approval from the European Commission to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

Big pharma stocks ought to perform well in the current high interest rate environment. Eli Lilly and Bristol Myers Squibb have long been top value plays.

I expected Bristol-Myers Squibb Company stock to keep rising in value through 2023 and perhaps reach triple figures. Instead, the share price has fallen 5% this year as inflationary headwinds and drug...

This monthly series ranks a selection of dividend growth stocks in Dividend Radar and presents the ten top-ranked stocks for consideration. To rank stocks, I sort them in descending order by quality s...

Despite dealing with a pharmaceutical company, Bristol-Myers Squibb's performance during recessions was mixed and the stock also performed horrible in the last two decades. For fiscal 2022, the compan...

Investors have assigned a higher multiple to LLY stock due to its robust pipeline and better profitability, as discussed below If we look at stock returns, Eli Lilly, with 15% returns in the last twel...

Look no further if you want yield and distribution growth in a large-cap name with a blue-chip appeal. A simple screen using Marketbeat.com's dividend screener will turn up names like Comcast (NASDAQ:...

Bristol Myers Squibb is counting on new approvals to fill the hole left by older medicines. Novo Nordisk is second to none in diabetes care, and it is expanding beyond this area.